IUB0271

IUB0271 (acyl-GIP) (100 nmol/kg; subcutaneous injection; single bolus/daily administration; 18 h/26 days) reduces acute food intake and achieves sustained reductions in body weight and fat mass in male diet-induced obese C57BL/6J wild-type mice via the GIPR signaling pathway in γ-aminobutyric acid (GABA)-ergic neurons. It fails to reduce acute food intake or induce sustained body weight loss in male diet-induced obese C57BL/6J Vgat-Gipr knockout mice, indicating that these effects depend on the GIPR signaling pathway in GABAergic neurons^[1].
IUB0271 (1 nmol/kg; subcutaneous injection; 30 min prior to tolerance testing) increases lipid tolerance by approximately 38% and improves glucose tolerance in obese male C57BL/6J mice^[2].
IUB0271 (150 nmol/kg; subcutaneous injection; single bolus) activates cFos expression in specific brain regions of male C57BL/6J wild-type mice fed a normal diet, but does not induce cFos activation in key brain regions of male C57BL/6J Vgat-Gipr knockout mice fed a normal diet^[1].
IUB0271 (1 nmol/kg; subcutaneous injection; single administration 30 min prior to gavage) enhances the clearance of plasma lipids into brown adipose tissue (BAT) by increasing lipoprotein lipase activity in BAT of obese male C57BL/6J mice by approximately 21%^[2].
IUB0271 (1 nmol/kg; subcutaneous injection; single administration 30 min before gavage; single administration at 11:00 a.m. for metabolic evaluation) increases lipid tolerance by approximately 28% and elevates systemic fatty acid oxidation levels by approximately 11% in obese male Gipr^BAT+/+ mice^[2].
IUB0271 (10 nmol/kg; subcutaneous injection; once daily for 28 consecutive days) improves dyslipidemia and reduces atherosclerotic plaque formation in male LDLR^-/- mice^[3].